Open AccessIxekizumab in radiographic axial spondyloarthritis with and without elevated C-reactive protein or positive magnetic resonance imaging
Author(s) -
Walter P. Maksymowych,
Rebecca Bolce,
Gaia Gallo,
Emily Seem,
Vladimir Geneus,
David Sandoval,
Mikkel Østergaard,
Kurisu Tada,
Xenofon Baraliakos,
Atul Deodhar,
Lianne S. Gensler
Publication year - 2022
Publication title -
rheumatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.957
H-Index - 173
eISSN - 1462-0332
pISSN - 1462-0324
DOI - 10.1093/rheumatology/keac104
Subject(s) - medicine , ixekizumab , axial spondyloarthritis , adalimumab , placebo , magnetic resonance imaging , gastroenterology , nuclear medicine , ankylosing spondylitis , tumor necrosis factor alpha , arthritis , pathology , radiology , psoriatic arthritis , alternative medicine , secukinumab , sacroiliitis
To evaluate response rates at week 16 with ixekizumab in patients with radiographic axial SpA (r-axSpA) and elevated or normal/low baseline inflammation measured by serum CRP or spinal MRI using data from two randomized, double-blind, placebo (PBO)-controlled phase III trials.